

Beth Karlan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6917803/publications.pdf>

Version: 2024-02-01

39
papers

2,080
citations

489802

18
h-index

406436

35
g-index

39
all docs

39
docs citations

39
times ranked

3640
citing authors

#	ARTICLE	IF	CITATIONS
1	DNA Methylation Profiles of Ovarian Clear Cell Carcinoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 132-141.	1.1	12
2	Cancer Risks Associated With <i>BRCA1</i> and <i>BRCA2</i> Pathogenic Variants. <i>Journal of Clinical Oncology</i> , 2022, 40, 1529-1541.	0.8	90
3	The risks of breast and ovarian cancer associated with the Ashkenazi Jewish founder allele <i>BRCA2</i> 6174delT. <i>Clinical Genetics</i> , 2022, 101, 317-323.	1.0	0
4	CA-125 Levels Are Predictive of Survival in Low-Grade Serous Ovarian Cancer—A Multicenter Analysis. <i>Cancers</i> , 2022, 14, 1954.	1.7	3
5	Bilateral Oophorectomy and the Risk of Breast Cancer in <i>BRCA1</i> Mutation Carriers: A Reappraisal. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 1351-1358.	1.1	3
6	Molecular Subclasses of Clear Cell Ovarian Carcinoma and Their Impact on Disease Behavior and Outcomes. <i>Clinical Cancer Research</i> , 2022, 28, 4947-4956.	3.2	22
7	Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 217-228.	1.1	12
8	Phase II trial of cisplatin, gemcitabine and pembrolizumab for platinum-resistant ovarian cancer. <i>PLoS ONE</i> , 2021, 16, e0252665.	1.1	13
9	Association of Germline BRCA Pathogenic Variants With Diminished Ovarian Reserve: A Meta-Analysis of Individual Patient-Level Data. <i>Journal of Clinical Oncology</i> , 2021, 39, 2016-2024.	0.8	36
10	Identification of a Locus Near <i>ULK1</i> Associated With Progression-Free Survival in Ovarian Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 1669-1680.	1.1	5
11	Weight Gain and the Risk of Ovarian Cancer in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 2038-2043.	1.1	6
12	Predicting master transcription factors from pan-cancer expression data. <i>Science Advances</i> , 2021, 7, eabf6123.	4.7	30
13	Does preventive oophorectomy increase the risk of depression in BRCA mutation carriers?. <i>Menopause</i> , 2020, 27, 156-161.	0.8	5
14	International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation. <i>British Journal of Cancer</i> , 2019, 121, 15-21.	2.9	101
15	Oophorectomy and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2019, 175, 443-449.	1.1	12
16	The association between smoking and cancer incidence in <i>BRCA1</i> and <i>BRCA2</i> mutation carriers. <i>International Journal of Cancer</i> , 2018, 142, 2263-2272.	2.3	20
17	Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation. <i>Gynecologic Oncology</i> , 2018, 150, 85-91.	0.6	65
18	Risk of breast cancer after a diagnosis of ovarian cancer in BRCA mutation carriers: Is preventive mastectomy warranted?. <i>Gynecologic Oncology</i> , 2017, 145, 346-351.	0.6	33

#	ARTICLE	IF	CITATIONS
19	Bilateral Oophorectomy and Breast Cancer Risk in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	160
20	The <i>BRCA1</i> -11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin. <i>Cancer Research</i> , 2016, 76, 2778-2790.	0.4	208
21	Digoxin therapy is not associated with improved survival in epithelial ovarian cancer: A SEER-Medicare database analysis. <i>Gynecologic Oncology</i> , 2016, 140, 285-288.	0.6	9
22	Hormone replacement therapy after menopause and risk of breast cancer in <i>BRCA1</i> mutation carriers: a case-control study. <i>Breast Cancer Research and Treatment</i> , 2016, 155, 365-373.	1.1	55
23	Treatment of infertility does not increase the risk of ovarian cancer among women with a <i>BRCA1</i> or <i>BRCA2</i> mutation. <i>Fertility and Sterility</i> , 2016, 105, 781-785.	0.5	38
24	Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: results from a large-scale collaboration. <i>Oncotarget</i> , 2016, 7, 72381-72394.	0.8	13
25	Germline polymorphisms in an enhancer of <i>PSIP1</i> are associated with progression-free survival in epithelial ovarian cancer. <i>Oncotarget</i> , 2016, 7, 6353-6368.	0.8	29
26	Germline Mutation in <i>BRCA1</i> or <i>BRCA2</i> and Ten-Year Survival for Women Diagnosed with Epithelial Ovarian Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 652-657.	3.2	138
27	A novel clinical trial recruitment strategy for women's cancer. <i>Gynecologic Oncology</i> , 2015, 138, 445-448.	0.6	6
28	Factors influencing ovulation and the risk of ovarian cancer in <i>BRCA1</i> and <i>BRCA2</i> mutation carriers. <i>International Journal of Cancer</i> , 2015, 137, 1136-1146.	2.3	56
29	Clinicopathological analysis of endometrial carcinomas harboring somatic <i>POLE</i> exonuclease domain mutations. <i>Modern Pathology</i> , 2015, 28, 505-514.	2.9	180
30	<i>BRCA1</i> germline mutations may be associated with reduced ovarian reserve. <i>Fertility and Sterility</i> , 2014, 102, 1723-1728.	0.5	114
31	Breast Cancer Following Ovarian Cancer in <i>BRCA</i> Mutation Carriers. <i>JAMA Surgery</i> , 2014, 149, 1306.	2.2	41
32	Impact of Oophorectomy on Cancer Incidence and Mortality in Women With a <i>BRCA1</i> or <i>BRCA2</i> Mutation. <i>Journal of Clinical Oncology</i> , 2014, 32, 1547-1553.	0.8	523
33	A cautious view of putative precursors of serous carcinomas in the fallopian tubes of <i>BRCA</i> mutation carriers. <i>Gynecologic Oncology</i> , 2014, 134, 492-497.	0.6	24
34	A phase II, multicenter, randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with carboplatin/paclitaxel as front-line therapy for optimally debulked primary ovarian cancer: The TRIO14 trial. <i>Journal of Clinical Oncology</i> , 2014, 32, 5529-5529.	0.8	3
35	The clinicopathologic significance of <i>FOXC1</i> in <i>BRCA</i> -mutant breast cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 1556-1556.	0.8	0
36	Utilizing Eastern Cooperative Oncology Group (ECOG) performance status scores to prevent harm with chemotherapy at the end of life. <i>Journal of Clinical Oncology</i> , 2014, 32, 146-146.	0.8	1

#	ARTICLE	IF	CITATIONS
37	A multicenter open-label phase II study of the efficacy and safety of ganitumab (AMG 479), a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R) as second-line therapy in patients with recurrent platinum-sensitive ovarian cancer.. Journal of Clinical Oncology, 2013, 31, 5515-5515.	0.8	12
38	Exposure-response relationship of open-label (OL) AMG 386 monotherapy in patients (pts) with recurrent ovarian cancer.. Journal of Clinical Oncology, 2012, 30, 5072-5072.	0.8	1
39	Validation of a Multivariate Serum Profile for Epithelial Ovarian Cancer Using a Prospective Multi-Site Collection. Nature Precedings, 2010, , .	0.1	1